Cassidy targets 340B, Eli Lilly's mysterious retatrutide patient, and more biotech news from The Readout
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Supreme Court rules in weedkiller cancer case | 0 | 5 | 26-06-2026 |
| 2 | The mysterious case of Eli Lilly’s obesity drug | 0 | 5 | 25-06-2026 |
| 3 | STAT+: Next-gen CRISPR tools improve editing accuracy in embryos, but also stoke ethical concerns | 0 | 7 | 25-06-2026 |
| 4 | STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better | 0 | 7 | 25-06-2026 |
| 5 | STAT+: Cassidy proposes bill to rein in 340B drug discount program | 0 | 5 | 25-06-2026 |
| 6 | STAT+: Pharmalittle: We’re reading about a bill to overhaul the 340B program, a new FDA commissioner candidate, and more | 0 | 3 | 26-06-2026 |
| 7 | STAT+: Democrats press White House on who got special access to Eli Lilly’s new obesity drug | 0 | 7 | 25-06-2026 |
| 8 | STAT+: European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine | 0 | 7 | 26-06-2026 |
| 9 | BIO 2026: AI, federal policy impacts, and general vibes | 0 | 5 | 26-06-2026 |
| 10 | Taxation With Representation: Sidley, Paul Weiss, Kirkland | 0 | 5 | 26-06-2026 |